APASL 2015 重要议题抢先看！

2015-03-03 国际肝病国际肝病

第24届亚太肝脏研究学会年会(APASL 2015)将于2015年3月11～15日在土耳其伊斯坦布尔召开。土耳其横跨欧亚两大洲，地理位置特殊，因此也是多种文化交融的中心。这是APASL年会首次在西亚举办。所以此次会议不仅吸引了亚太国家的学者，也同时吸引了中东、欧洲、非洲和美国的专家学者。 APASL年会的课程水平不断提高，摘要投稿和继续教育课程数量逐渐增加。大会主席土耳其安卡拉大学A Kadir

第24届亚太肝脏研究学会年会(APASL 2015)将于2015年3月11～15日在土耳其伊斯坦布尔召开。

土耳其横跨欧亚两大洲，地理位置特殊，因此也是多种文化交融的中心。这是APASL年会首次在西亚举办。所以此次会议不仅吸引了亚太国家的学者，也同时吸引了中东、欧洲、非洲和美国的专家学者。 APASL年会的课程水平不断提高，摘要投稿和继续教育课程数量逐渐增加。

大会主席土耳其安卡拉大学A Kadir Dokmeci教授此前在接受记者采访时谈到，“williamhill asia 已经从全世界邀请了200多名非常杰出的讲者，有许多来自亚太国家，还有许多重要讲者来自欧洲、美国以及其他国家。截止目前，williamhill asia 已经收到1200多篇摘要投稿，预期将有5000多名参会者。”

会议首日将以会前课程、继续教育和临床研究方法学工作组为主，讨论肝移植、内镜、肝炎、基础科学和研究方法学。

随后四天将以特邀演讲、全体会议、专家见面会、口头报告、壁报、卫星会等多种形式进行学术交流;此外，APASL与AASLD、EASL等学会组织将继续举办联合会议。讲题内容涉及肝脏病学各个领域，其中以丙型肝炎、乙型肝炎、肝细胞肝癌、肝硬化和慢加急性肝衰竭(ACLF)为主要内容。

此次会议上，APASL将专门召开乙型肝炎威廉亚洲博彩公司会议，而WHO也将通过专题会议发布WHO乙型肝炎威廉亚洲博彩公司。

部分重要议题如下：

3月12日

乙型肝炎威廉亚洲博彩公司会议

3月13日

OKUDA特邀演讲

丙型肝炎治疗的终极目标 Masao Omata

GURAKAR特邀演讲

门静脉高压症有哪些新进展? Shiv K. Sarin

大会报告：东西方肝脏病学新视点

ALT正常患者何时应该接受治疗? George Lau

ANA阳性而ALT正常患者应该治疗吗? Lee Guan Huei

门静脉血栓患者需要接受抗凝治疗吗? Jose Sollano

门静脉高压症患者何时停用β受体阻滞剂? Guadalupe Garcia-Tsao

APASL-AASLD联合会议

HBV DNA低于104 copies/mL的患者应该治疗吗? Masao Omata/Adrian M. Di Bisceglie

HCV RNA阳性而ALT正常的患者应该治疗吗? Gyongyi Szabo/George Lau

3月14日

ZAFER PAYKO?特邀演讲

肝细胞肝癌的治疗：切除到射频 A.Kadir D?kmeci

大会报告：东西方肝纤维化的新视点

肝纤维化机制 Massimo Pinzani

不同病因的肝纤维化差异 Nancy Leung

抗纤维化治疗 George Lau

抗病毒治疗对肝纤维化的影响 Anna Lok

WHO专题会议：WHO乙型肝炎威廉亚洲博彩公司发布

APASL-EASL联合会议

亚欧乙型肝炎抗病毒治疗药物的不同 Osamu Yokosuka/Patrick Marcellin

未来丙型肝炎治疗中，干扰素是否必需? Darrell Crawford/Alessio Aghemo

3月15日

ZAFER PAYKO?特邀演讲

乙型肝炎的过去、现在和未来 Anna Lok

全体会议23-会议亮点

2015年乙型肝炎的挑战 Shiv Sarin

丙型肝炎 Masao Omata

肝细胞肝癌 George Lau

版权声明：
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于williamhill asia 医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章，或“williamhill asia 号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系，williamhill asia 将立即进行删除处理。
在此留言

评论区 (4)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1338134, encodeId=1237133813420, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2620, encryptionId=cd2a262068, topicName=APA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Thu Mar 05 02:13:00 CST 2015, time=2015-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1519201, encodeId=2214151920170, content=<a href='/topic/show?id=2082286e7b' target=_blank style='color:#2F92EE;'>#ASL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2867, encryptionId=2082286e7b, topicName=ASL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1a311248160, createdName=lq1771, createdTime=Thu Mar 05 02:13:00 CST 2015, time=2015-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598433, encodeId=3df015984330c, content=<a href='/topic/show?id=a8952625e5' target=_blank style='color:#2F92EE;'>#APASL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2625, encryptionId=a8952625e5, topicName=APASL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b18118584502, createdName=tongyongming, createdTime=Thu Mar 05 02:13:00 CST 2015, time=2015-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17547, encodeId=65301e547d2, content=超赞，好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=177, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Wed Mar 04 10:45:00 CST 2015, time=2015-03-04, status=1, ipAttribution=)]
2015-03-05 12498b3em08(暂无昵称)

#APA#

0 0
[GetPortalCommentsPageByObjectIdResponse(id=1338134, encodeId=1237133813420, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2620, encryptionId=cd2a262068, topicName=APA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Thu Mar 05 02:13:00 CST 2015, time=2015-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1519201, encodeId=2214151920170, content=<a href='/topic/show?id=2082286e7b' target=_blank style='color:#2F92EE;'>#ASL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2867, encryptionId=2082286e7b, topicName=ASL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1a311248160, createdName=lq1771, createdTime=Thu Mar 05 02:13:00 CST 2015, time=2015-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598433, encodeId=3df015984330c, content=<a href='/topic/show?id=a8952625e5' target=_blank style='color:#2F92EE;'>#APASL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2625, encryptionId=a8952625e5, topicName=APASL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b18118584502, createdName=tongyongming, createdTime=Thu Mar 05 02:13:00 CST 2015, time=2015-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17547, encodeId=65301e547d2, content=超赞，好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=177, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Wed Mar 04 10:45:00 CST 2015, time=2015-03-04, status=1, ipAttribution=)]
2015-03-05 lq1771

#ASL#

0 0
[GetPortalCommentsPageByObjectIdResponse(id=1338134, encodeId=1237133813420, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2620, encryptionId=cd2a262068, topicName=APA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Thu Mar 05 02:13:00 CST 2015, time=2015-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1519201, encodeId=2214151920170, content=<a href='/topic/show?id=2082286e7b' target=_blank style='color:#2F92EE;'>#ASL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2867, encryptionId=2082286e7b, topicName=ASL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1a311248160, createdName=lq1771, createdTime=Thu Mar 05 02:13:00 CST 2015, time=2015-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598433, encodeId=3df015984330c, content=<a href='/topic/show?id=a8952625e5' target=_blank style='color:#2F92EE;'>#APASL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2625, encryptionId=a8952625e5, topicName=APASL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b18118584502, createdName=tongyongming, createdTime=Thu Mar 05 02:13:00 CST 2015, time=2015-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17547, encodeId=65301e547d2, content=超赞，好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=177, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Wed Mar 04 10:45:00 CST 2015, time=2015-03-04, status=1, ipAttribution=)]
2015-03-05 tongyongming

#APASL#

83 0
[GetPortalCommentsPageByObjectIdResponse(id=1338134, encodeId=1237133813420, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2620, encryptionId=cd2a262068, topicName=APA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Thu Mar 05 02:13:00 CST 2015, time=2015-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1519201, encodeId=2214151920170, content=<a href='/topic/show?id=2082286e7b' target=_blank style='color:#2F92EE;'>#ASL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2867, encryptionId=2082286e7b, topicName=ASL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1a311248160, createdName=lq1771, createdTime=Thu Mar 05 02:13:00 CST 2015, time=2015-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598433, encodeId=3df015984330c, content=<a href='/topic/show?id=a8952625e5' target=_blank style='color:#2F92EE;'>#APASL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2625, encryptionId=a8952625e5, topicName=APASL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b18118584502, createdName=tongyongming, createdTime=Thu Mar 05 02:13:00 CST 2015, time=2015-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17547, encodeId=65301e547d2, content=超赞，好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=177, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Wed Mar 04 10:45:00 CST 2015, time=2015-03-04, status=1, ipAttribution=)]
2015-03-04 xiaoai5777

超赞，好文章

177 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

肝病

APASL 2015 重要议题抢先看！

相关威廉亚洲官网

科室

工具

服务